AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2021
May 28, 2021
31949_dirs_2021-05-28_5bf768bc-3cca-46f5-bb63-78bd43fd37ce.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-05-27
Reporting Person: Benaim Ely (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-27 | Ordinary Shares | M | 1833 | $47.56 | Acquired | 30887 | Direct |
| 2021-05-27 | Ordinary Shares | S | 1833 | $200 | Disposed | 29054 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-27 | Options to Buy Ordinary Shares | $47.56 | M | 1833 | Disposed | 2029-05-07 | Ordinary Shares (1833.0) | Direct |
Footnotes
F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.
F2: Fully vested as of the date hereof.
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3